The economic impact of disease progression and death in hormone receptor positive (HR+), human epidermal growth factor receptor 2 negative (HER2-) advanced breast cancer patients: using Korean nationwide health insurance claims data

References

• Khan FA, Akhtar SS, Sheikh MKJT, Mjoms M. Cancer treatment-objectives and quality of life issues. Malays J Med Sci. 2005;12(1):3–5.
   PubMedGoogle Scholar
• Oxnard GR, Morris MJ, Hodi FS, et al. When progressive disease does not mean treatment failure: reconsidering the criteria for progression. J Natl Cancer Inst. 2012;104(20):1534–1541.
   PubMedGoogle Scholar
• Sherrill B, Amonkar M, Wu Y, et al. Relationship between effects on time-to-disease progression and overall survival in studies of metastatic breast cancer. Br J Cancer. 2008;99(10):1572–1578.
   PubMed Web of Science ®Google Scholar
• Tripathy D, Im SA, Colleoni M, et al. Ribociclib plus endocrine therapy for premenopausal women with hormone-receptor-positive, advanced breast cancer (MONALEESA-7): a randomised phase 3 trial. Lancet Oncol. 2018;19(7):904–915.
   PubMed Web of Science ®Google Scholar
• Fox KM, Brooks JM, Kim J. Metastatic non-small cell lung cancer: costs associated with disease progression. Am J Manag Care. 2008;14(9):565–571.
   PubMed Web of Science ®Google Scholar
• Penson DF, Moul JW, Evans CP, et al. The economic burden of metastatic and prostate specific antigen progression in patients with prostate cancer: findings from a retrospective analysis of health plan data. J Urol. 2004;171(6 Part 1):2250–2254.
   PubMed Web of Science ®Google Scholar
• Sun L, Legood R, dos-Santos-Silva I, et al. Global treatment costs of breast cancer by stage: a systematic review. PLOS One. 2018;13(11):e0207993.
   PubMed Web of Science ®Google Scholar
• Park M, Song I. Medical care costs of cancer in the last year of life using national health insurance data in Korea. PLOS One. 2018;13(6):e0197891.
   PubMed Web of Science ®Google Scholar
• Kim H, Yang D-W, Kang E. Cancer care costs at the end of life. Korean J Health Econ Pol. 2017;23(1):123–142.
   Google Scholar
• Tanuseputro P, Wodchis WP, Fowler R, et al. The health care cost of dying: a population-based retrospective cohort study of the last year of life in Ontario, Canada. PLOS One. 2015;10(3):e0121759.
   PubMed Web of Science ®Google Scholar
• Gray AM, Clarke PM, Wolstenholme JL, et al. Applied methods of cost-effectiveness analysis in healthcare. Vol. 3. New York (NY): Oxford University Press; 2011.
   Google Scholar
• Gravelle H, Brouwer W, Niessen L, et al. Discounting in economic evaluations: stepping forward towards optimal decision rules. Health Econ. 2007;16(3):307–317.
   PubMed Web of Science ®Google Scholar
• Ramsey S, Willke R, Briggs A, et al. Good research practices for cost-effectiveness analysis alongside clinical trials: the ISPOR RCT-CEA task force report. Value Health. 2005;8(5):521–533.
   PubMed Web of Science ®Google Scholar
• Finn RS, Martin M, Rugo HS, et al. Palbociclib and letrozole in advanced breast cancer. N Engl J Med. 2016;375(20):1925–1936.
   PubMed Web of Science ®Google Scholar
• Johnston S, Martin M, Di Leo A, et al. MONARCH 3 final PFS: a randomized study of abemaciclib as initial therapy for advanced breast cancer. NPJ Breast Cancer. 2019;5:5.
   PubMed Web of Science ®Google Scholar
• Turner NC, Slamon DJ, Ro J, et al. Overall survival with palbociclib and fulvestrant in advanced breast cancer. N Engl J Med. 2018;379(20):1926–1936.
   PubMed Web of Science ®Google Scholar
• Im SA, Lu YS, Bardia A, et al. Overall survival with ribociclib plus endocrine therapy in breast cancer. N Engl J Med. 2019;381(4):307–316.
   PubMed Web of Science ®Google Scholar
• Sledge GW, Jr, Toi M, Neven P, et al. The effect of abemaciclib plus fulvestrant on overall survival in hormone receptor–positive, ERBB2-negative breast cancer that progressed on endocrine therapy—MONARCH 2: a randomized clinical trial. JAMA Oncol. 2020;6(1):116–124.
   PubMed Web of Science ®Google Scholar
• You JM, Kim YG, Moon H-G, et al. Survival improvement in Korean breast cancer patients due to increases in early-stage cancers and hormone receptor positive/HER2 negative subtypes: a nationwide registry-based study. J Breast Cancer. 2015;18(1):8–15.
   PubMed Web of Science ®Google Scholar
• Kwon S. Thirty years of national health insurance in South Korea: lessons for achieving universal health care coverage. Health Policy Plan. 2009;24(1):63–71.
   PubMed Web of Science ®Google Scholar
• Hao Y, Li N, Fang AP, et al. Real-world analysis of medical costs and healthcare resource utilization in elderly women with HR+/HER2- metastatic breast cancer receiving everolimus-based therapy or chemotherapy. Adv Ther. 2016;33(6):983–997.
   PubMed Web of Science ®Google Scholar
• Swallow E, Zhang J, Thomason D, et al. Real-world patterns of endocrine therapy for metastatic hormone-receptor-positive (HR+)/human epidermal growth factor receptor-2-negative (HER2-) breast cancer patients in the United States: 2002–2012. Curr Med Res Opin. 2014;30(8):1537–1545.
   PubMed Web of Science ®Google Scholar
• Health Insurance Review & Assessment Service. Details on the application criteria of reimbursement on medications for cancer patients: notice 2018–21. In: Health Insurance Review & Assessment Service. Korea; 2017. http://www.hira.or.kr/bbsDummy.do?pgmid=HIRAA030023010000. [Korean]
   Google Scholar
• Gradishar WJ, Anderson BO, Abraham J, et al. NCCN clinical practice guidelines in oncology: breast cancer. Version 3rd ed. Plymouth Meeting, PA: National Comprehensive Cancer Network; 2018.
   Google Scholar
• Burton T, Byfield SD, Smith GL, et al. Clinical and economic outcomes by first-line treatment among women with HR+/HER2- metastatic breast cancer in a large US health plan database. Curr Med Res Opin. 2016;32(8):1417–1423.
   PubMed Web of Science ®Google Scholar
• Lage MJ, Borker R, Barber B, et al. Healthcare costs in postmenopausal women with hormone-positive metastatic breast cancer. J Med Econ. 2010;13(4):691–697.
   PubMedGoogle Scholar
• Kim JA, Yoon S, Kim LY, et al. Towards actualizing the value potential of Korea Health Insurance Review and Assessment (HIRA) data as a resource for health research: strengths, limitations, applications, and strategies for optimal use of HIRA data. J Korean Med Sci. 2017;32(5):718–728.
   PubMed Web of Science ®Google Scholar
• Thapa D, Rastogi V, Ahuja V. Cancer pain management-current status. J Anaesthesiol Clin Pharmacol. 2011;27(2):162–168.
   PubMedGoogle Scholar
• Patijn J, de Rijke J, van den Beuken-van Everdingen M, et al. Prevalence of pain in patients with cancer: a systematic review of the past 40 years. Ann Oncol. 2007;18(9):1437–1449.
   PubMed Web of Science ®Google Scholar
• Gupta M, Sahi MS, Bhargava AK, et al. The prevalence and characteristics of pain in critically ill cancer patients: a prospective nonrandomized observational study. Indian J Palliat Care. 2015;21(3):262–267.
   PubMed Web of Science ®Google Scholar
• Husereau D, Drummond M, Petrou S, CHEERS Task Force, et al. Consolidated health economic evaluation reporting standards (CHEERS) statement. Value Health. 2013;16(2):e1-5–e5.
   PubMed Web of Science ®Google Scholar
• Reyes C, Engel-Nitz NM, DaCosta Byfield S, et al. Cost of disease progression in patients with metastatic breast, lung, and colorectal cancer. The Oncol. 2019;24(9):1209–1218.
   PubMed Web of Science ®Google Scholar
• Ray S, Bonthapally V, McMorrow D, et al. Patterns of treatment, healthcare utilization and costs by lines of therapy in metastatic breast cancer in a large insured US population. J Comp Eff Res. 2013;2(2):195–206.
   PubMed Web of Science ®Google Scholar
• Altundag K, Basaran G, Oksuzoglu B, et al. Cost of treatment of HR+/HER2- post menopausal advanced/metastatic breast cancer patients in Turkey. Value Health. 2016;19(3):A146.
   Web of Science ®Google Scholar
• Anders CK, Johnson R, Litton J, et al. Breast cancer before age 40 years. Semin Oncol. 2009;36(3):237–249.
   PubMed Web of Science ®Google Scholar
• de la Rochefordiere A, Asselain B, Campana F, et al. Age as prognostic factor in premenopausal breast carcinoma. Lancet. 1993;341(8852):1039–1043.
   PubMed Web of Science ®Google Scholar
• Assi HA, Khoury KE, Dbouk H, et al. Epidemiology and prognosis of breast cancer in young women. J Thorac Dis. 2013;5(1):S2–S8.
   PubMedGoogle Scholar
• Goto R, Uda A, Hiroi S, et al. Cost analysis of leuprorelin acetate in Japanese pre-menopausal breast-cancer patients: comparison between 6-month and 3-month depot formulations. J Med Econ. 2017;20(11):1163–1169.
   PubMed Web of Science ®Google Scholar